Ribeirão Preto Medical School, University of São Paulo
Ribeirão Preto, São Paulo, 14049900, Brazil
Location status: Recruiting
NCT Number: NCT07646522
The purpose of this research study is to provide preliminary evidence of whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone in Brazil. Evaluate the safety and feasibility of telerehabilitation in the Brazilian context. Explore the clinical, neuroimaging, neurophysiological, and economic factors that influence telerehabilitation efficacy in functional recovery following stroke.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Phase 2
Ribeirão Preto, São Paulo, 14049900, Brazil
Location status: Recruiting
This is a two-arm phase II randomized controlled trial with blinded outcome assessment. A total of 20 post-stroke participants will be randomized to either telerehabilitation added to usual care (TR+UC) or usual care alone (UC). The primary outcome measure is the Action Research Arm Test (ARAT), which assesses upper extremity motor function. Secondary measures will include feasibility and intervention-related outcomes.
Study participation will span approximately 4 months and includes 6 in-person assessment visits. At these visits, participants will complete a battery of assessments, including upper extremity motor function tests, resting-state functional electroencephalography (EEG), and a single magnetic resonance imaging (MRI) scan of the brain. Participants assigned to the TR+UC group will receive structured arm motor training consisting of 36 sessions of prescribed exercises, interactive games, and stroke education delivered over 6 weeks at a frequency of 6 days per week, with each session lasting approximately 70 minutes. TR+UC participants will continue all usual care concurrently. Participants in the UC group will continue all therapies recommended by their medical team without participating in telerehabilitation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive 36 telerehabilitation sessions targeting arm motor function in addition to their usual care. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently.
Usual care rehabilitation refers to the recommendations made by their care team.
Time frame: From baseline to early (within 7 days) post-intervention
Change in Action Research Arm Test (ARAT) Score from baseline to the early post-intervention. The ARAT scale measures arm function using a scale that runs from 0 to 57 points, with higher numbers reflecting better arm function.
Time frame: Through recruitment completion - an average of 15 months
Proportion of eligible participants who agree to take part in the study.
Time frame: Through study completion (specifically end of therapy) - an average of 17 months
Proportion of participants who complete TR therapy with sessions of 40 minutes or longer.
Time frame: Through study completion (specifically end of follow-up) - an average of 18 months
Proportion of dropouts during the study participation period.
Time frame: From baseline to 1 month post-intervention
Change in Action Research Arm Test (ARAT) Score from baseline to 1 month post-intervention. The ARAT scale measures arm function using a scale that runs from 0 to 57 points, with higher numbers reflecting better arm function.
Time frame: From the start of TR to early (within 7 days) post-intervention
Number and severity of adverse events related to the telerehabilitation intervention reported by the participants.
Time frame: Baseline
Cortical spinal tract integrity - lesion load (predictive factor).
Time frame: Baseline
rs-fMRI interhemispheric functional connectivity in the primary motor cortex (predictive factor).
Time frame: Baseline
nTMS motor mapping (predictive factor).
Time frame: Baseline
rsEEG interhemispheric functional connectivity in the primary motor cortex (predictive factor).
Time frame: From baseline to early (within 7 days) post-intervention
Change in UE-FM. UE-FM is a scale that measures upper limb motor function using a scale that runs from 0 to 66 points, with higher scores reflecting better upper extremity motor function.
Time frame: From baseline to early (within 7 days) post-intervention
Change in mRS. The mRS scale measures global function using a scale that runs from 0 to 6 points, with lower numbers reflecting better global function.
Time frame: From baseline to early (within 7 days) post-intervention
Change in rsEEG interhemispheric functional connectivity in the primary motor cortex.
Time frame: From baseline to 1-month post-intervention
Change in rsEEG interhemispheric functional connectivity in the primary motor cortex.
Time frame: From baseline to early (within 7 days) post-intervention
nTMS motor mapping (predictive factor).
Time frame: From baseline to 1 month post-intervention
nTMS motor mapping (predictive factor).
Interested in participating?
Request InfoUniversity of Sao Paulo
Other
Telerehabilitation and Biomarkers of Functional Recovery After Stroke in Brazil: TR-BR-1 Clinical Trial
Acronym: TR-BR-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07520032
Brain Diseases, Cardiovascular Diseases
Ajman, Ajman Emirate, United Arab Emirates
View Trial DetailsNCT07579871
Apnea, Brain Diseases
Lund, Skåne County, Sweden
View Trial DetailsNCT07698522
Brain Diseases, Cardiovascular Diseases
Salt Lake City, Utah, United States
View Trial DetailsNCT06891690
Adnexal Diseases, Brain Diseases
Poznan, Poland
View Trial Details